Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis
NCT07329101Phase 1Completed
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VC-005 in atopic dermatitis (AD), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoints: Area Under the Curve From Time Zero to Last Quantifiable Concentration at Day 28 and Peak Plasma Concentration at Day 28. Started Nov 2025; status: completed.
02
Drugs
VC-005
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07329101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07329101.